Effect of biological DMARDs and JAK inhibitors in pain of chronic inflammatory arthritis
INTRODUCTION: The advent of biological disease-modifying anti-rheumatic drugs (bDMARDs) and, more recently, of Janus kinase inhibitors (JAKi) has had a major impact on the long-term outcomes of chronic inflammatory arthritis (IA). However, the persistence of pain, even in patients with a complete pharmacological control of peripheral inflammation, represents an important clinical challenge in the treatment of IA.
AREAS COVERED: In this review, we provide an overview of possible mechanisms underlying pain in IA and its assessment, as well as the effects of bDMARDs and JAKi on pain management.
EXPERT OPINION: The overall data showed a good effect of bDMARDs and JAKi on pain, which is more pronounced for JAKi. However, it is challenging to distinguish the effect on the different types of pain (nociceptive, neuropathic, and nociplastic).
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:22 |
|---|---|
| Enthalten in: |
Expert opinion on biological therapy - 22(2022), 10 vom: 11. Okt., Seite 1311-1322 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Alciati, Alessandra [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antirheumatic Agents |
|---|
| Anmerkungen: |
Date Completed 21.10.2022 Date Revised 01.12.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1080/14712598.2022.2130243 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM346845777 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM346845777 | ||
| 003 | DE-627 | ||
| 005 | 20231226032428.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/14712598.2022.2130243 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1156.xml |
| 035 | |a (DE-627)NLM346845777 | ||
| 035 | |a (NLM)36168970 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Alciati, Alessandra |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Effect of biological DMARDs and JAK inhibitors in pain of chronic inflammatory arthritis |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 21.10.2022 | ||
| 500 | |a Date Revised 01.12.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a INTRODUCTION: The advent of biological disease-modifying anti-rheumatic drugs (bDMARDs) and, more recently, of Janus kinase inhibitors (JAKi) has had a major impact on the long-term outcomes of chronic inflammatory arthritis (IA). However, the persistence of pain, even in patients with a complete pharmacological control of peripheral inflammation, represents an important clinical challenge in the treatment of IA | ||
| 520 | |a AREAS COVERED: In this review, we provide an overview of possible mechanisms underlying pain in IA and its assessment, as well as the effects of bDMARDs and JAKi on pain management | ||
| 520 | |a EXPERT OPINION: The overall data showed a good effect of bDMARDs and JAKi on pain, which is more pronounced for JAKi. However, it is challenging to distinguish the effect on the different types of pain (nociceptive, neuropathic, and nociplastic) | ||
| 650 | 4 | |a Review | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a DMARDs | |
| 650 | 4 | |a JAKIs | |
| 650 | 4 | |a MCID | |
| 650 | 4 | |a pain | |
| 650 | 4 | |a psoriatic arthritis | |
| 650 | 4 | |a rheumatoid arthritis | |
| 650 | 7 | |a Janus Kinase Inhibitors |2 NLM | |
| 650 | 7 | |a Antirheumatic Agents |2 NLM | |
| 700 | 1 | |a Di Carlo, Marco |e verfasserin |4 aut | |
| 700 | 1 | |a Siragusano, Cesare |e verfasserin |4 aut | |
| 700 | 1 | |a Palumbo, Antonino |e verfasserin |4 aut | |
| 700 | 1 | |a Masala, Ignazio Francesco |e verfasserin |4 aut | |
| 700 | 1 | |a Atzeni, Fabiola |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Expert opinion on biological therapy |d 2001 |g 22(2022), 10 vom: 11. Okt., Seite 1311-1322 |w (DE-627)NLM116190124 |x 1744-7682 |7 nnns |
| 773 | 1 | 8 | |g volume:22 |g year:2022 |g number:10 |g day:11 |g month:10 |g pages:1311-1322 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/14712598.2022.2130243 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 22 |j 2022 |e 10 |b 11 |c 10 |h 1311-1322 | ||